Literature DB >> 2564429

A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671.

M A Luther1, R Schoepfer, P Whiting, B Casey, Y Blatt, M S Montal, M Montal, J Linstrom.   

Abstract

The human neuromedulloblastoma cell line TE671 is shown by single-channel recordings to express nicotinic acetylcholine receptors (AChRs) that are blocked by alpha-bungarotoxin (alpha Bgt). These AChRs do not react with antisera to the alpha Bgt-binding protein of brain or with monoclonal antibodies (mAbs) to brain nicotinic AChRs that do not bind alpha Bgt. TE671 AChRs do react with autoantibodies to muscle AChRs from myasthenia gravis patients and with mAbs to muscle AChRs, including mAbs specific for extrajunctional AChRs. AChRs. AChRs purified from TE671 cells are composed of 4 kinds of subunits corresponding to those of muscle AChR. Sequences of cDNAs for the ACh-binding alpha subunit and the delta subunit of this AChR further identify it as muscle AChR. Expression of TE671 AChR can be up-regulated by nicotine and dexamethasone, and down-regulated by forskolin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564429      PMCID: PMC6569985     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  32 in total

1.  Slow-channel myasthenic syndrome caused by enhanced activation, desensitization, and agonist binding affinity attributable to mutation in the M2 domain of the acetylcholine receptor alpha subunit.

Authors:  M Milone; H L Wang; K Ohno; T Fukudome; J N Pruitt; N Bren; S M Sine; A G Engel
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

2.  A comparison of MyoD1 and fetal acetylcholine receptor expression in childhood tumors and normal tissues: implications for the molecular diagnosis of minimal disease in rhabdomyosarcomas.

Authors:  S Gattenloehner; B Dockhorn-Dworniczak; I Leuschner; A Vincent; H K Müller-Hermelink; A Marx
Journal:  J Mol Diagn       Date:  1999-11       Impact factor: 5.568

3.  Neuronal-type alpha-bungarotoxin receptors and the alpha 5-nicotinic receptor subunit gene are expressed in neuronal and nonneuronal human cell lines.

Authors:  B Chini; F Clementi; N Hukovic; E Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

Review 4.  Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.

Authors:  W E Melroy-Greif; J A Stitzel; M A Ehringer
Journal:  Genes Brain Behav       Date:  2015-12-23       Impact factor: 3.449

5.  Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients.

Authors:  S J Tzartos; M Remoundos
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

6.  The role of the amino acid residue at alpha1:189 in the binding of neuromuscular blocking agents to mouse and human muscle nicotinic acetylcholine receptors.

Authors:  P G Purohit; R J Tate; E Pow; D Hill; J G Connolly
Journal:  Br J Pharmacol       Date:  2007-02-12       Impact factor: 8.739

7.  hnRNP H enhances skipping of a nonfunctional exon P3A in CHRNA1 and a mutation disrupting its binding causes congenital myasthenic syndrome.

Authors:  Akio Masuda; Xin-Ming Shen; Mikako Ito; Tohru Matsuura; Andrew G Engel; Kinji Ohno
Journal:  Hum Mol Genet       Date:  2008-09-20       Impact factor: 6.150

Review 8.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 9.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

10.  T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits.

Authors:  A A Manfredi; M P Protti; M W Dalton; J F Howard; B M Conti-Tronconi
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.